Deruxtecan 2-hydroxypropanamide

• CAT Number: I040077
• CAS Number: 2577204-16-9
• Molecular Formula: C27H26FN3O6
• Molecular Weight: 507.51
• Purity: ≥95%
• Synonyms: (2S)-N-[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]-2-hydroxypropanamide
• InChI: InChI=1S/C27H26FN3O6/c1-4-27(36)16-7-20-23-14(9-31(20)25(34)15(16)10-37-26(27)35)22-18(30-24(33)12(3)32)6-5-13-11(2)17(28)8-19(29-23)21(13)22/h7-8,12,18,32,36H,4-6,9-10H2,1-3H3,(H,30,33)/t12-,18-,27-/m0/s1
• InChIKey: UOCFLIUBXYLYLD-BEMWVBDCSA-N
• SMILES: CCC1(C2=C(COC1=O)C(=O)N3CC4=C5C(CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)NC(=O)C(C)O)O

Deruxtecan 2-hydroxypropanamide (Cat No.: I040077) is a potent topoisomerase I inhibitor used as a payload in antibody-drug conjugates (ADCs) for targeted cancer therapy research. It disrupts DNA replication and induces apoptosis in tumor cells, enhancing anticancer efficacy. The 2-hydroxypropanamide modification improves solubility, stability, and bioavailability, optimizing drug delivery. Ideal for oncology drug discovery and ADC development, it enables tumor-selective cytotoxicity while minimizing systemic toxicity, making it a crucial tool for advancing next-generation precision medicine and targeted cancer treatments.

Reference

[1]. Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof. World Intellectual Property Organization, et al. World Intellectual Property Organization, WO2021249228 A1 2021-12-16.